Recital 13, Regulation (EU) 2020/1043

In forcesince 15 Jul 2020

In this situation of public health emergency, it is of major interest for the Union that safe and efficacious medicinal products intended to treat or prevent COVID-19 can be developed and be made available within the Union as soon as possible.